Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a4afb11b9038232a630fc22a300b2717 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-183 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-18 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 |
filingDate |
2020-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9b659ab9f5585a96d50c1213b686fcf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b36efe10f2b86f7d30c3e2004a2ee787 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1dcea44172eee7b92421b656ed28aa0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5caa5f03a9c8a7ca967e8f7c44cffa4f |
publicationDate |
2020-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2020114843-A |
titleOfInvention |
Liquid pharmaceutical composition containing teriparatide having excellent stability |
abstract |
PROBLEM TO BE SOLVED: 1) The liquid pharmaceutical preparation in which the production of a deamidated product of teriparatide or a salt thereof is suppressed, and 2) the liquid pharmaceutical preparation in which the production of an aspartic acid residue isomerization product of teriparatide or a salt thereof is suppressed. 3) To provide the liquid pharmaceutical preparation, which is stable for a long period of time, and 4) The liquid pharmaceutical preparation, in which the production of an oxidized form of teriparatide or a salt thereof is suppressed. SOLUTION: In order to suppress the formation of a deamidated form of teriparatide acetate during storage of a liquid pharmaceutical preparation for human subcutaneous administration containing teriparatide acetate, the formulation is selected from sodium chloride and sodium acetate. One or more kinds of salts are contained, and the pH of the preparation is set to 3.6 to 5.0. [Selection diagram] None |
priorityDate |
2017-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |